Amphastar Pharmaceuticals Cash on Hand 2012-2026 | AMPH
Amphastar Pharmaceuticals cash on hand from 2012 to 2026. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
|
Amphastar Pharmaceuticals Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2025 | $285 |
| 2024 | $224 |
| 2023 | $259 |
| 2022 | $178 |
| 2021 | $139 |
| 2020 | $110 |
| 2019 | $90 |
| 2018 | $93 |
| 2017 | $72 |
| 2016 | $74 |
| 2015 | $67 |
| 2014 | $69 |
| 2013 | $55 |
| 2012 | $52 |
|
Amphastar Pharmaceuticals Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2026-06-30 | $293 |
| 2026-03-31 | $294 |
| 2025-12-31 | $285 |
| 2025-09-30 | $279 |
| 2025-06-30 | $234 |
| 2025-03-31 | $239 |
| 2024-12-31 | $224 |
| 2024-09-30 | $253 |
| 2024-06-30 | $220 |
| 2024-03-31 | $292 |
| 2023-12-31 | $259 |
| 2023-09-30 | $306 |
| 2023-06-30 | $168 |
| 2023-03-31 | $195 |
| 2022-12-31 | $178 |
| 2022-09-30 | $187 |
| 2022-06-30 | $186 |
| 2022-03-31 | $189 |
| 2021-12-31 | $139 |
| 2021-09-30 | $117 |
| 2021-06-30 | $139 |
| 2021-03-31 | $118 |
| 2020-12-31 | $110 |
| 2020-09-30 | $103 |
| 2020-06-30 | $103 |
| 2020-03-31 | $71 |
| 2019-12-31 | $90 |
| 2019-09-30 | $102 |
| 2019-06-30 | $127 |
| 2019-03-31 | $86 |
| 2018-12-31 | $93 |
| 2018-09-30 | $76 |
| 2018-06-30 | $55 |
| 2018-03-31 | $62 |
| 2017-12-31 | $72 |
| 2017-09-30 | $74 |
| 2017-06-30 | $87 |
| 2017-03-31 | $79 |
| 2016-12-31 | $74 |
| 2016-09-30 | $69 |
| 2016-06-30 | $68 |
| 2016-03-31 | $65 |
| 2015-12-31 | $67 |
| 2015-09-30 | $72 |
| 2015-06-30 | $76 |
| 2015-03-31 | $70 |
| 2014-12-31 | $69 |
| 2014-09-30 | $74 |
| 2014-06-30 | $66 |
| 2014-03-31 | $53 |
| 2013-12-31 | $55 |
| 2012-12-31 | $52 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.019B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |